JP Morgan Chase
ENZ

JP Morgan Chase’s Enzo Biochem, Inc. ENZ Stock Holding History

JP Morgan Chase’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,915
Closed -$708 – 7857
2025
Q1 		$708 Sell
1,915
-8
-0.4% -$4 ﹤0.01% 6667
2024
Q4 		$1.37K Buy
1,923
+90
+5% +$93 ﹤0.01% 6689
2024
Q3 		$2.05K Hold
1,833
– – ﹤0.01% 6618
2024
Q2 		$2K Hold
1,833
– – ﹤0.01% 6528
2024
Q1 		$2.33K Hold
1,833
– – ﹤0.01% 6557
2023
Q4 		$2.55K Hold
1,833
– – ﹤0.01% 6683
2023
Q3 		$2.57K Hold
1,833
– – ﹤0.01% 6504
2023
Q2 		$3.37K Hold
1,833
– – ﹤0.01% 6250
2023
Q1 		$4K Buy
1,833
+1,763
+2,519% +$2.62K ﹤0.01% 6312
2022
Q4 		$0 Hold
70
– – ﹤0.01% 7083
2022
Q3 		$0 Hold
70
– – ﹤0.01% 6933
2022
Q2 		$0 Hold
70
– – ﹤0.01% 6968
2022
Q1 		$0 Hold
70
– – ﹤0.01% 7100
2021
Q4 		$0 Hold
70
– – ﹤0.01% 7031
2021
Q3 		$0 Sell
70
-107,650
-100% -$359K ﹤0.01% 6880
2021
Q2 		$341K Sell
107,720
-31,552
-23% -$99.2K ﹤0.01% 4944
2021
Q1 		$478K Buy
139,272
+7,057
+5% +$21.9K ﹤0.01% 4709
2020
Q4 		$334K Buy
132,215
+111,227
+530% +$242K ﹤0.01% 4592
2020
Q3 		$43K Buy
20,988
+6,047
+40% +$14.4K ﹤0.01% 4987
2020
Q2 		$33K Sell
14,941
-50,352
-77% -$129K ﹤0.01% 4948
2020
Q1 		$166K Buy
65,293
+39,331
+151% +$96.6K ﹤0.01% 4343
2019
Q4 		$68K Buy
25,962
+9,325
+56% +$27.9K ﹤0.01% 5028
2019
Q3 		$60K Buy
16,637
+4,516
+37% +$16K ﹤0.01% 5101
2019
Q2 		$43K Buy
12,121
+1,377
+13% +$4.85K ﹤0.01% 5235
2019
Q1 		$29K Sell
10,744
-13,448
-56% -$44K ﹤0.01% 5306
2018
Q4 		$67K Sell
24,192
-40,885
-63% -$134K ﹤0.01% 4985
2018
Q3 		$268K Buy
65,077
+16,386
+34% +$74.4K ﹤0.01% 4577
2018
Q2 		$252K Sell
48,691
-117,273
-71% -$715K ﹤0.01% 4472
2018
Q1 		$910K Buy
165,964
+157,079
+1,768% +$1.11M ﹤0.01% 3723
2017
Q4 		$72K Sell
8,885
-15,792
-64% -$151K ﹤0.01% 4779
2017
Q3 		$263K Buy
+24,677
New +$274K ﹤0.01% 4025
2017
Q2 		– Sell
-26,241
Closed -$220K – 5278
2017
Q1 		$220K Buy
+26,241
New +$185K ﹤0.01% 4036
2016
Q2 		– Sell
-45,167
Closed -$206K – 4996
2016
Q1 		$206K Buy
+45,167
New +$201K ﹤0.01% 3611
2013
Q4 		– Sell
-21,476
Closed -$54K – 4266
2013
Q3 		$54K Sell
21,476
-300
-1% -$711 ﹤0.01% 4252
2013
Q2 		$45K Buy
+21,776
New +$48.1K ﹤0.01% 4282

Other funds holding ENZ

RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
KCM
Kempner Capital Management Galveston, Texas $106M AUM 29.1% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

JP Morgan Chase's ENZ Position: Q2 2025 in Review

JP Morgan Chase sold out of Enzo Biochem, Inc. (ENZ) in Q2 2025, closing a stake of 1,915 shares — an estimated $708 sold.

JP Morgan Chase first reported a position in ENZ in Q2 2013 and held it in 35 quarters. The position peaked at $910K in Q1 2018. 6 funds tracked by Wall St. Rank hold ENZ as of Q2 2025.

  • JP Morgan Chase reported no remaining Enzo Biochem, Inc. position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 1,915 Enzo Biochem, Inc. shares in Q2 2025, an estimated $708.
  • JP Morgan Chase first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 35 quarters.
  • JP Morgan Chase's Enzo Biochem, Inc. position peaked at $910K in Q1 2018.
  • 6 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.